JB Chemicals & Pharmaceuticals

JB Chemicals & Pharmaceuticals has reported 13 per cent rise in profit after tax at Rs 111 crore for the second quarter ended September 30, 2022. The drug firm had logged a profit after tax (PAT) of Rs 98 crore in July-September period of previous fiscal year. Revenue rose to Rs 809 crore in the period under review as compared with Rs 593 crore in the year-ago quarter, it said in a statement. "Our market-beating performance in domestic business was sustained through growth in our organic portfolio, with big brands getting bigger; and significant demand acceleration in acquired brands which have seamlessly transitioned in a short period," company CEO and Wholetime Director Nikhil Chopra said. The momentum in the international business continued across markets, with all three of the company's verticals performing well, he added. "Our strategic focus on key brands, segments and geographies is resulting in a consistent, sustained revenue growth. "And this growth, along with ...

Among individual stocks, the technical analyst recommends buying JK Tyre and J.B.Chemicals & Pharma.

JB Chemicals & Pharmaceuticals on Thursday said its board has approved a proposal to acquire four paediatric brands from Dr Reddy's Laboratories for about Rs 98 crore. The company's board at its meeting held on June 29, has considered and approved the acquisition of a portfolio of brands, for use sales within India, from Dr Reddy's Laboratories, the drug maker said in a regulatory filing. The company has inked a pact with Dr Reddy's Laboratories to acquire four of its brands -- Z&D, Pedicloryl, Pecef and Ezinapi -- for the India market, it added. All four brands are focused on the paediatric segment in the country with a total covered market size of Rs 1,800 crore as per IQVIA data, JB Chemicals & Pharmaceuticals said. The combined sales of these brands stood at around Rs 33 crore for FY 2021-22, it added. The acquisition, which will be funded primarily through long-term debt, will be completed in the next few working days, the drug firm stated.

JB Chemicals now plan to enter new areas like sleep disorders, sexual wellness, motion sickness, and immunity apart, from the conventional areas like cough, sore throat, etc.

Drug firm JB Chemicals & Pharmaceuticals on Thursday reported a consolidated net profit of Rs 119.05 crore for the quarter ended on June 30, 2021. The company had posted a net profit of Rs 119.50 crore for the corresponding period of the previous fiscal, JB Chemicals & Pharmaceuticals said in a filing to BSE. Consolidated revenue from operations of the company stood at Rs 606 crore for the quarter under consideration. It was Rs 522.3 crore for the same period a year ago, it added. "The organisation continues its strong performance well in the first quarter of the financial year. On the domestic front, we are one of the fastest growing companies in the industry," JBCPL CEO and Wholetime Director Nikhil Chopra said. While demand trends in international business continue to be volatile (given the COVID situation); the company's key markets like the US, South Africa have outperformed and even Russia/ CIS are seeing gradual signs of revival, he added. Shares of JB Chemicals & ..

Drug firm JB Chemicals & Pharmaceuticals on Monday reported a two-fold jump in consolidated net profit to Rs 100.81 crore for the quarter ended March 2021 on account of robust sales. The company had posted a net profit of Rs 50.07 crore for the corresponding period of the previous fiscal year, JB Chemicals & Pharmaceuticals said in a regulatory filing. Consolidated revenue from operations stood at Rs 528 crore for the quarter under consideration. It was Rs 444 crore for the same period a year ago, it added. For the full fiscal 2020-21, the net profit of the company was Rs 449 crore as against Rs 272 crore for the previous year, the filing said. Revenue from operations for the fiscal year ended March 2021 stood at Rs 2,043 crore. It was Rs 1,775 crore in FY20. The board of directors has recommended a final dividend of Rs 8 per equity share of face value of Rs 2 for the financial year 2020-21, it added. "Our financial performance for FY21 has been encouraging in one of the most .

Key chronic segments have helped the JB Chemicals outperform the Indian pharma market.

The board has declared interim dividend of Rs 8.50 per equity share of face value of Rs 2 (425 per cent) for FY21

With the former Cipla head at the helm, JB Chemicals now plans to diversify into paediatrics and respiratory

In the past six months, the stock has soared 82 per cent against 25 per cent rise in the S&P BSE Sensex.

The company's revenue came in at Rs 522.28 crore, up 17 per cent against Rs 446.11 crore in the corresponding quarter of the previous fiscal.

All that happened in the markets today

The total deal size thus will be around $500 mn or around Rs 3,750 crore

After this transaction, an open offer will be launched to acquire 20.93 million fully paid-up equity shares of JB Chemicals, representing 26 per cent of equity.

From states divided on alternative GST compensation, Emami questioning changing of 'Fair and Handsome' name to startups helping tenant amid Covid-19, here are the top headlines of the day

The stock of Syngene International has soared 24 per cent during the past month, as against a 2 per cent rise in the S&P BSE Sensex.

Till May 15, the overall inventory was 39 days, compared to 43 days in first half of the previous month

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Lack of fresh prescriptions drags growth in acute therapies

Sale of anti-infectives (11% of domestic pharma market) fell by 21.5%, while gynaecological and dermatological drugs fell by about 23%